Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Group 1 - Lexicon Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(a)(2) as its common stock has maintained a closing bid price of $1.00 or greater for ten consecutive business days [1] - The update regarding compliance was previously disclosed in the Company's Current Report on Form 8-K filed on July 28, 2025 [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company utilizes its Genome5000™ program to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential across various diseases [2] - Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in areas such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]